LENZ Therapeutics, a biopharmaceutical company dedicated to developing the first and only eye drop based on aceclidine (LNZ100) to improve near vision in presbyopia patients.

Bispecific antibodies (commonly abbreviated as BsAbs) are an innovative class of biological drugs capable of simultaneously binding to two different antigens or epitopes.

The launch of the bispecific DLL3/CD3 antibody Tarlatamab marks a significant turning point for targeting DLL3.

at the ESC Congress, Bayer published the pooled analysis of the Phase III FINE-HEART study on finerenone, along with the latest data from the FINEARTS-HF trial.

Antibody-Drug Conjugates (ADCs), as a part of precision medicine, target tumor cells by combining the specificity of antibodies with the potent effects of cytotoxins.

NewBridge will have exclusive distribution rights in Algeria, Iraq, Libya, and Jordan for CRYSVITA® (burosumab) for the treatment of X-linked hypophosphatemia (XLH) and tumor-induced osteomalacia (TIO).

Recently, Merus announced that the first patient has been dosed in the phase 3 clinical trial LiGeR-HN2.

On July 26, Belgian biotech company Confo Therapeutics (Confo) announced that it has completed a €60 million Series B financing round.

On June 24, Viking Therapeutics presented preclinical data of their in-house developed Dual Agonists of Amylin and Calcitonin Receptors (DACARs) .

With the completion of this acquisition, RayzeBio has brought BMS a promising pipeline of radiotherapeutic drugs, including its key project RYZ101 (225Ac-DOTATATE).

Johnson & Johnson has halted the development of their co-created anti-epileptic drug, ADX71149 (JNJ-40411813), with Addex Therapeutics after analyzing Phase 2 clinical data.

The paper discusses the identification of a novel negative allosteric modulator of the µ-opioid receptor (µOR) through screening with a DNA-encoded small molecule library.